Transmembrane protein 220 (TMEM220)

Transmembrane protein 220 (TMEM220) is a human protein encoded by the TMEM220 gene located on chromosome 17[1][9]. It is predicted to be a membrane-associated protein, though its precise structure and physiological function remain incompletely characterized[1][3][7]. TMEM220 has been reported as downregulated in tumor tissues, particularly in hepatocellular carcinoma (HCC), where lower expression correlates with poor prognosis. Experimental evidence indicates that overexpression of TMEM220 in cancer cell lines suppresses proliferation and metastasis, potentially through modulation of pathways involving FOXO and PI3K-Akt and affecting cell cycle regulators such as p21 and migration regulator SNAIL[2]. TMEM220 is thus being investigated as a prognostic biomarker and potential therapeutic target in cancer, especially HCC, but no clinically approved drugs or direct mechanisms of drug action have been reported to date[2][9]. The broader transmembrane protein (TMEM) family is known for diverse roles in signal transduction, cell adhesion, migration, and other key cellular processes, and several members are implicated as biomarkers or targets in cancer and other diseases[6]. Key points: - TMEM220 is not currently associated with any approved drugs or targeted therapies. - Its main documented role is as a putative tumor suppressor and prognostic biomarker in liver cancer[2][9]. - It is considered a candidate of interest for further therapeutic research, but many functional and pharmacological details remain unknown.

Other names

TMEM220